AstraZeneca, Ionis Win A Key US FDA Approval With Wainua For ATTR Polyneuropathy

Drug Launches In January Under Co-Commercialization Deal

 
• By Mandy Jackson

AstraZeneca adds an important product to its cardiovascular, renal and metabolism (CVRM) portfolio and Ionis gains the first drug it will commercialize as it prepares for its first wholly owned launch.

FDA Approved text on white notepad paper near folders
Wainua is the first patient-administered drug for ATTR-PN • Source: Shutterstock

More from New Products

More from Scrip